23/09/2024 – AB Science today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference Download PDF Post navigationPreviousPrevious post:Positive results of the Phase 2 study evaluating masitinib in Covid-19NextNext post:AB Science provides an update on the microtubule program AB8939Related PostsSummary of the webcast held on January 28, 202529 January 2025Summary of the webcast held on December 16, 202417 December 2024AB Science webcast of December 16, 202416 December 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET11 December 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
